Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Podcast: Providence’s COVID-19 mRNA Vaccine Challenger Seen In Phase III In Q1

Canadian Firm To Raise Further $400m

Oct 06 2021

• By Vibha Ravi

Scrip Podcast Special — Audio interview with Providence CEO Brad Sorenson

Related Content

How Pfizer Crafted Its Own ‘Operation Warp Speed’ For The COVID-19 Vaccine

Jun 24 2021

Moderna Sees COVID-19 Vaccine Surplus By 2022 If Constraints Ease

Apr 26 2021

Indian Biotech In mRNA Push As COVID-19 Vaccine Moves To Phase II

Aug 26 2021

Podcast: Ex-Hilleman CEO On COVID-19 Vaccine Heterologous Boosting, Endemic Disease

Sep 28 2021

AstraZeneca Moves Into Self-Amplifying RNA With VaxEquity Deal

Sep 23 2021

Chinese Biotechs' Foray Into mRNA Enters New Chapter With $100m Everest Deal

Sep 15 2021

Related Companies

Pfizer Inc.

Moderna, Inc.

Providence Therapeutics Holdings Inc.

Biological E Limited.

Everest Medicines Limited

Emergent BioSolutions, Inc.

Northern Therapeutics Inc.

Additional Topics

Canada India Asia Pacific China Coronavirus COVID-19 Vaccines Research & Development Business Strategies Clinical Trials BioPharmaceutical Respiratory

More from COVID-19

More from Scrip

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.